BERTILIMUMAB

BERTILIMUMAB

Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

NANOMABS

NANOMABS

NanomAbs is Immune's promising new-generation nanotechnology platform for cancer therapy. It is developed towards targeted, enhanced delivery of chemotherapeutics to cancer patients with potential reduction in off-target side effects. Read More 

CEPLENE

CEPLENE

Ceplene® immunotherapy (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML). Read More 

Latest News

NEWS May 2, 2016

Immune Pharmaceuticals is mentioned on Roth Capital’s focus list of microcap biotech stocks | Read more 

 

NEWS April 21, 2016

Immune Presents Biomarker Data On Ceplene at AACR | Read more 

 

NEWS April 19, 2016

New Ceplene® Biomarker Data Poster Presented at AACR Published | Read more 

 

See All News 

Upcoming Events

No upcoming events found

See All Events